Literature DB >> 21282714

Deferiprone or deferasirox for cardiac siderosis in beta-thalassemia major.

Khaled M Musallam, Ali T Taher.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21282714      PMCID： PMC3031678          DOI： 10.3324/haematol.2010.036061

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  9 in total

1.  Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in beta-thalassaemia.

Authors:  Lisa J Anderson; Beatrix Wonke; Emma Prescott; Sally Holden; J Malcolm Walker; Dudley J Pennell
Journal:  Lancet       Date:  2002-08-17       Impact factor: 79.321

2.  Cardiac morbidity and mortality in deferoxamine- or deferiprone-treated patients with thalassemia major.

Authors:  Caterina Borgna-Pignatti; Maria Domenica Cappellini; Piero De Stefano; Giovanni Carlo Del Vecchio; Gian Luca Forni; Maria Rita Gamberini; Roberta Ghilardi; Antonio Piga; Maria Antonietta Romeo; Huaqing Zhao; Avital Cnaan
Journal:  Blood       Date:  2005-12-22       Impact factor: 22.113

3.  Efficacy of deferasirox in reducing and preventing cardiac iron overload in beta-thalassemia.

Authors:  Dudley J Pennell; John B Porter; Maria Domenica Cappellini; Amal El-Beshlawy; Lee Lee Chan; Yesim Aydinok; Mohsen Saleh Elalfy; Pranee Sutcharitchan; Chi-Kong Li; Hishamshah Ibrahim; Vip Viprakasit; Antonis Kattamis; Gillian Smith; Dany Habr; Gabor Domokos; Bernard Roubert; Ali Taher
Journal:  Blood       Date:  2009-12-08       Impact factor: 22.113

4.  The effect of deferasirox on cardiac iron in thalassemia major: impact of total body iron stores.

Authors:  John C Wood; Barinder P Kang; Alexis Thompson; Patricia Giardina; Paul Harmatz; Tara Glynos; Carole Paley; Thomas D Coates
Journal:  Blood       Date:  2010-04-26       Impact factor: 22.113

5.  Deferasirox, deferiprone and desferrioxamine treatment in thalassemia major patients: cardiac iron and function comparison determined by quantitative magnetic resonance imaging.

Authors:  Alessia Pepe; Antonella Meloni; Marcello Capra; Paolo Cianciulli; Luciano Prossomariti; Cristina Malaventura; Maria Caterina Putti; Alma Lippi; Maria Antonietta Romeo; Maria Grazia Bisconte; Aldo Filosa; Vincenzo Caruso; Antonella Quarta; Lorella Pitrolo; Massimiliano Missere; Massimo Midiri; Giuseppe Rossi; Vincenzo Positano; Massimo Lombardi; Aurelio Maggio
Journal:  Haematologica       Date:  2010-09-30       Impact factor: 9.941

6.  Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis.

Authors:  Dudley J Pennell; Vasili Berdoukas; Markissia Karagiorga; Vasili Ladis; Antonio Piga; Athanassios Aessopos; Efstathios D Gotsis; Mark A Tanner; Gill C Smith; Mark A Westwood; Beatrix Wonke; Renzo Galanello
Journal:  Blood       Date:  2005-12-13       Impact factor: 22.113

7.  Myocardial iron clearance during reversal of siderotic cardiomyopathy with intravenous desferrioxamine: a prospective study using T2* cardiovascular magnetic resonance.

Authors:  Lisa J Anderson; Mark A Westwood; Sally Holden; Bernard Davis; Emma Prescott; Beatrix Wonke; John B Porter; J Malcolm Walker; Dudley J Pennell
Journal:  Br J Haematol       Date:  2004-11       Impact factor: 6.998

8.  Improving survival with deferiprone treatment in patients with thalassemia major: a prospective multicenter randomised clinical trial under the auspices of the Italian Society for Thalassemia and Hemoglobinopathies.

Authors:  Aurelio Maggio; Angela Vitrano; Marcello Capra; Liana Cuccia; Francesco Gagliardotto; Aldo Filosa; Carmelo Magnano; Michele Rizzo; Vincenzo Caruso; Calogera Gerardi; Crocetta Argento; Saveria Campisi; Francesco Cantella; Francesca Commendatore; Domenico Giuseppe D'Ascola; Carmelo Fidone; Angela Ciancio; Maria Concetta Galati; Gaetano Giuffrida; Rocca Cingari; Giovanni Giugno; Turi Lombardo; Luciano Prossomariti; Roberto Malizia; Anna Meo; Gaetano Roccamo; Maria Antonietta Romeo; Pietro Violi; Paolo Cianciulli; Paolo Rigano
Journal:  Blood Cells Mol Dis       Date:  2009-02-23       Impact factor: 3.039

Review 9.  Cardiac iron across different transfusion-dependent diseases.

Authors:  John C Wood
Journal:  Blood Rev       Date:  2008-12       Impact factor: 8.250
  9 in total
  2 in total

1.  Simultaneous field and R2 mapping to quantify liver iron content using autoregressive moving average modeling.

Authors:  Brian A Taylor; Ralf B Loeffler; Ruitian Song; M Beth McCarville; Jane S Hankins; Claudia M Hillenbrand
Journal:  J Magn Reson Imaging       Date:  2011-12-16       Impact factor: 4.813

2.  Longitudinal monitoring of cardiac siderosis using cardiovascular magnetic resonance T2* in patients with thalassemia major on various chelation regimens: a 6-year study.

Authors:  Srikanth R Ambati; Rachel E Randolph; Kevin Mennitt; Dorothy A Kleinert; Jonathan W Weinsaft; Patricia J Giardina
Journal:  Am J Hematol       Date:  2013-06-28       Impact factor: 10.047
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.